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Abstract
Background: CagA cellular interaction via activation of the ERK signaling pathway may be a starting point in the
development of gastric cancer. This study aimed to evaluate whether genes involved in ERK downstream signaling
pathways activated by CagA are susceptible genetic markers for gastric cancer.
Methods: In the discovery phase, a total of 580 SNPs within +/25 kbp of 30 candidate genes were genotyped to examine
an association with gastric cancer risk in the Korean Multi-center Cancer Cohort (100 incident gastric cancer case-control
sets). The most significant SNPs (raw or permutated p value,0.02) identified in the discovery analysis were re-evaluated in
the extension phase using unconditional logistic regression model (400 gastric cancer case-control sets). Combined analyses
including pooled- and meta-analysis were conducted to summarize all the results.
Results: 24 SNPs in eight genes (ERK, Dock180, C3G, Rap1, Src, CrkL, Mek and Crk) were significantly associated with gastric
cancer risk in the individual SNP analyses in the discovery phase (p,0.05). In the extension analyses, ERK rs5999749,
Dock180 rs4635002 and C3G rs7853122 showed marginally significant gene-dose effects for gastric cancer. Consistently,
final combined analysis presented the SNPs as significantly associated with gastric cancer risk (OR=1.56, [95% CI: 1.19–2.06],
OR=0.61, [95% CI: 0.43–0.87], OR=0.59, [95% CI: 0.54–0.76], respectively).
Conclusions: Our findings suggest that ERK rs5999749, Dock180 rs4635002 and C3G rs7853122 are genetic determinants in
gastric carcinogenesis.
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Introduction
Helicobacter pylori (H. pylori) is a proven cause of gastric
carcinogenesis [1]. Nevertheless, its absolute effect can be modified
by individual susceptibility risk factors such as genetic variants and
H. pylori virulent characteristics [2,3]. Cytotoxin-associated antigen
(CagA), a H. pylori immunoprotein, is a crucial factor for individual
susceptibility and is associated with severe clinical outcomes
including gastric cancer [4,5,6]. In gastric epithelial cells, CagA
interferes with diverse signal transduction pathways, such as
Dock180-Rac1-WAVE-Arp2/3, C3G-Rap1-BRaf-MEK, Sos1-
HRas-Raf1, and Ras-Raf-MEK-ERK signaling [3,7,8,9]. Signals
modified by CagA induce cellular changes such as apoptosis, pro-
liferation, and cell mortality, and stimulate gastric carcinogenesis
[10,11,12].
Among several downstream pathways activated by CagA, the
extracellular signal-regulated kinase (ERK) cascade is a core path-
way as it plays an important role in gastric carcinogenesis. CagA
cellular interactions with Src, SHP2, Crk, CrkL or GRB2 are
significantly associated with ERK activation, and other diverse
proteins involved in CagA signaling are intimately connected to
ERK signal pathways [10,11,12,13]. Proteins can be regulated by
their host genes; therefore, genes encoding proteins related to
CagA and ERK signaling process may be important for gastric
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e21155carcinogenesis but few studies have focused on these genetic
polymorphisms.
CagA oncogenicity may be a starting point in the development
of gastric cancer via activation of the ERK signal pathway. These
signal transductions appear to be modified by host genetic variants.
Thus, we hypothesized that genes involved in the ERK downstream
signaling pathways activated by CagA may be susceptible genetic
markers for gastric cancer. To evaluate this hypothesis, we con-
ducted a multi-stage genetic association study that included 1) dis-
covery phase: a candidate gene analysis that focused on 30 genes,
Crk, CrkL, Csk, GRB2, c-Met, NFATC4, PTPN11, SMS, SOS1,
Src, ERK, FAK, PLCc, KRAS, NRAS, BRAF, RAF1, MAP2K1,
MAP2K3, MAP2K4, MAP2K5, MAP2K6, p21, Dock180, RA-
C1,RAP1,WAVE,Arp2,Arp3 andC3G, involved inthe CagAand
ERK signal transduction pathway, and 2) extension phase that




Discovery phase. The discovery candidate gene analysis was
a population-based nested case-control study within the Korean
Multi-Center Cancer Cohort (KMCC). From 1993 to 2004, the
KMCC recruited a total of 19,688 participants from four urban
and rural areas in Korea. All participants completed detailed
standardized questionnaires by personal interview after informed
consent. Blood and urine samples were also collected. Through
record linkages to the national death certificate, the health insur-
ance medical records databases and the national cancer registry,
all participants were passively followed-up, and newly diagnosed
cases were ascertained. Detailed information about the KMCC is
described elsewhere [14]. In December of 2005, 249 gastric cancer
cases defined according to the International Statistical Classi-
fication of Diseases and Related Health Problems 10th Revision
(ICD-10, C16) were identified. Cases diagnosed before recruit-
ment (n=52), with no blood samples (n=35), or insufficient DNA
level under 50 ng/ml (n=62) were excluded. Cancer-free controls
were matched by age (65 years), sex, residential district, and
enrollment year. Finally, 100 sets of gastric cancer cases and
matched controls were defined.
Extension phase. 1) In December 2008, 95 new gastric
cancer cases were additionally ascertained from the KMCC.
These cases and 116 cases that were excluded in the discovery
cohort due to prevalence status or inadequate DNA concentration
were included in the extension phase (n=211). Using the same
matching method as the discovery phase, 211 controls were se-
lected. 2) Gastric cancer cases were obtained from two university
hospitals in Korea that were Chungnam University Hospital and
Hanyang University GURI Hospital. From March 2002 to Sep-
tember 2006, a total of 490 gastric cancer patients were newly
diagnosed at the hospitals. Their epidemiological data and venous
whole blood samples were collected at the time of diagnosis or
prior to gastric cancer surgery. Among them, 189 cases with suffi-
cient DNA samples and informed consents were also included in
the extension set. Also, 189 community-based controls were matched
by age (65 years) and sex from the KMCC subjects enrolled after
2000.
Ethics Statement
The study protocols for the KMCC study, the hospital-based
study and the current nested case-control study were approved
by the institutional review boards (IRB) of Seoul National
University Hospital and the National Cancer Center of Korea
(H-0110-084-002 and C-0603-161-170) and by the institutional
review board of Hanyang University Hospital (IRB no. 2003-4).
Gene and SNP selection
Through literature review, we indentified 30 candidate genes
that may be involved in the CagA signal transduction pathway
linked to ERK downstream signaling by direct interaction with
CagA or secondary affection in CagA genetic sequences [3,7,8,
9,10,11,12]. The 30 candidate genes are as follows: v-Crk sarcoma
virus CT10 oncogene homolog (CRK); v-Crk sarcoma virus CT10
oncogene homolog (avian)-like (CRKL); c-Src tyrosine kinase (CSK);
growth factor receptor-bound protein 2 (GRB2); Met proto-on-
cogene (c-MET); nuclear factor of activated T-cells, cytoplasmic,
calcineurin-dependent 4 (NFATC4); protein tyrosine phosphatase,
non-receptor type 11 (PTPN11); spermine synthase (SMS); son of
sevenless homolog 1(SOS1); v-Src sarcoma (Schmidt-Ruppin A-2)
viral oncogene homolog (SRC); elk-related tyrosine kinase (ERK);
focal adhesion kinase 1 (FAK); phospholipase C-gamma (PLCc); v-
Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS);
neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS); v-raf
murine sarcoma viral oncogene homolog B1 (BRAF); v-raf-1 murine
leukemia viral oncogene homolog 1 (RAF1); mitogen-activated
protein kinase kinase 1 (MAP2K1); mitogen-activated protein kinase
kinase 3 (MAP2K3); mitogen-activated protein kinase kinase 4
(MAP2K4); mitogen-activated protein kinase kinase 5 (MAP2K5);
mitogen-activated protein kinase kinase 6 (MAP2K6); cyclin-depen-
dent kinase inhibitor 1A (p21); dedicator of cytokinesis 1 (Dock180);
ras-relatedC3botulinumtoxinsubstrate1 (RAC1);RAP1A member
of RAS oncogene family (RAP1); WAS protein family, member 1
(WAVE); ARP2 actin-related protein 2 homolog (Arp2); ARP3 actin-
related protein 3 homolog (Arp3); Rap guanine nucleotide exchange
factor (GEF) 1 (C3G).
Genotyping
Discovery phase. Genotyping was performed using the
genome-wide human SNP Array 5.0 according to the standard
protocol recommended by the manufacturer’s instructions [15].
Before genotyping, concentrations of genomic DNA for all study
subjects were measured using a spectrophotometer (NanoDrop
ND-1000, NanoDrop Technologies). For each individual assayed,
250 ng of genomic DNA was digested with a restriction enzyme
(Nsp I or Sty I). Though we screened a total of 580 SNPs within +/
25 kbp of the 30 target gene locations, 103 polymorphisms were
excluded due to a SNP call rate of less than 95% or a HWE value
less than 0.0001. Because the genome-wide human SNP Array 5.0
was manufactured based on a Caucasian population, 115 SNPs
did not meet the criteria of MAF,0.05 in Asians and were also
excluded. Additionally, 20 cases and 14 controls were excluded
due to insufficient genomic DNA (,250 ng), sex discordance or
poor genotyping (,90%). Finally, 362 SNPs in 30 genes
(genotyping rate of 99.5%) were genotyped in 81 cases and 85
controls. The cluster images of signal intensity were reviewed for
all SNPs.
Extension phase. S e v e nS N P sw i t hr a wo rp e r m u t a t e d
p value,0.02 (rs5999749, rs9418677, rs4635002, rs10901081,
rs7853122, rs530801, rs747182) identified in the discovery analysis
were genotyped using the Illumina VeraCode GoldenGate Assay
with BeadXpress according to the manufacturer’s protocol (Illu-
mina, San Diego, CA, USA) [16]. To ensure the reliability of the
two genotyping methods, 135 samples (59 cases and 76 controls)
were genotyped twice by both the genome-wide human SNP Array
5.0 and the Illumina VeraCode GoldenGate Assay, and the
concordance rate was .98.2%. Of the 7 SNPs, rs9418677 was
excluded due to a SNP call rate ,95%. Two cases and 40 controls
ERK, CagA and Gastric Cancer
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(n=27) were also excluded in the analysis. Finally, six SNPs in five
genes (genotyping rate of 99.1%) were analyzed in 398 cases and
360 controls in the extension phase.
H. pylori and CagA detection
H. pylori infection status and CagA seropositivity were evaluated
using immunoblot assay, Helico Blot 2.1
TM (MP Biomedicals Asia
Pacific, Singapore). Helico Blot 2.1
TM kits have reported a sen-
sitivity of 99% for both H.pylori and CagA seropositivity and a
specificity of 98% for H. pylori and 90% for CagA seropositivity
[17].
Statistical analysis
The Hardy-Weinberg equilibrium (HWE) in the control group
was evaluated by Fisher’s exact test with a cut-off level of HWE
,0.0001.
In the primary scan in the discovery set, the association between
individual SNPs and gastric cancer risk was evaluated based on
both raw and permutated p-values using the LRT with 1 degree of
freedom in the trend (additive) model. The trend test assumes a
dose-response effect with an increasing number of variant alleles.
Permutated p-values were estimated by 100,000 permutation tests.
Based on the additive model, gastric cancer risk was calculated as
odds ratios (ORs) and 95% confidence intervals (CIs) using
unconditional logistic regression model adjusting for risk factors
that were smoking status (ever vs. never), H. pylori infection (positive
vs. negative) and CagA seropositivity (positive vs. negative). The
Benjamini-Hochberg false discovery rate (BH-FDR) corrected p-
values of each SNP was computed to avoid spurious association
with false positive outcomes [18].
In the extension phase, the most significant SNPs with raw or
permutated p value,0.02 identified in the discovery phase were
re-evaluated. Based on the additive model, gastric cancer risk was
estimated as ORs and 95% CIs using unconditional logistic
regression model adjusting for risk factors that were smoking status
(ever vs. never), H. pylori infection (positive vs. negative) and CagA
seropositivity (positive vs. negative). To summarize the results
from the discovery and the extension analyses, data-pooling and
meta-analysis were conducted. The summary ORs and 95% CIs
were calculated using a fixed-effect model and heterogeneity was
evaluated by the Cochran Q statistics [19].
All statistical analyses were performed using SAS software
version 9.1 (SAS Institute, Cary, North Carolina) and PLINK
software version 1.06 (http://pngu.mgh.harvard.edu/purcell/plink)
[20]. Meta-analyses were conducted using STATA version 10 (Stata,
College Station, TX).
Results
Table 1 summarizes basic characteristics of the study partici-
pants in each phase. Gastric cancer cases showed significantly
higher rates of CagA seropositivity (p=0.03 in discovery phase,
p=0.09 in extension phase and p=0.02 among total subjects). H.
pylori infection, VacA seropositivity and smoking status were also
higher among gastric cancer cases (Table 1).
In the primary scan of the discovery set, of the 362 SNPs se-
lected from CagA-related genes in the signal transduction pathway,
24 SNPs in eight genes, ERK, Dock180, C3G, Rap1, Src, CrkL,
Mek and Crk, were significantly associated with gastric cancer risk
in the single SNP analysis (p,0.05). According to the 100,000
permutation test, ERK rs5999749 and Dock180 rs9418677 pre-
sented a stronger association with gastric cancer (p,0.01). These
SNPs showed significant gene-dose effects in the linear trend test
and were significantly associated with an increased risk of gastric
cancer (OR=2.83, [95% CI: 1.42–5.65] for ERK rs5999749;
OR=1.90, [95% CI: 1.18–3.05] for Dock180 rs9418677). Except
for Dock180 rs9418677 and Rap1 rs17028287, most SNPs
downstream from CagA-Crk signaling (Dock180, C3G, Rap1
and Mek) were significantly associated with a reduced risk of gastric
cancer (Table 2).
In the extension phase, all associations between the selected
SNPs and gastric cancer risk were relatively attenuated. ERK
rs5999749, Dock180 rs4635002 and C3G rs7853122 showed
significant gene-dose effect for gastric cancer (OR=1.40, [95%
CI: 1.04–1.89]; OR=0.65, [95% CI: 0.44–0.94]; OR=0.61,
[95% CI: 0.46–0.81], respectively). In the final combined analysis
that included the discovery and extension analyses, the risk
estimates of ERK rs5999749 were significantly associated with
gastric cancer in both the pooled analysis and meta-analysis
Table 1. Basic characteristics of the study populations: Discovery and extension sets of community controls and gastric cancer
cases from the KMCC, Chungnam University Hospital and Hanyang University GURI Hospital.
Discovery phase
a Extension phase













Age Mean (SD) 64.2 (67.9) 63.3 (68.0) 0.44 61.6 (610.4) 63.2 (68.3) 0.02 62.0 (610.1) 63.2 (68.2) 0.06
Sex Female 26 (32.1) 26 (30.6) 0.83 131 (32.9) 115 (31.9) 0.78 157 (32.8) 141 (31.7) 0.72
H.pylori infection Positive (+) 72 (88.9) 68 (80.0) 0.11 353 (88.7) 309 (85.8) 0.24 425 (88.7) 377 (84.7) 0.07
CagA Positive (+) 78 (96.3) 74 (87.1) 0.03 366 (91.9) 318 (88.3) 0.09 444 (92.7) 392 (88.1) 0.02
VacA Positive (+) 50 (61.7) 46 (54.1) 0.32 279 (70.1) 240 (66.7) 0.31 329 (68.7) 286 (64.3) 0.16
Smoking status
c Ever smokers 52 (64.2) 47 (55.3) 0.24 247 (62.1) 196 (54.4) 0.10 300 (62.6) 243 (54.6) 0.01
Drink status
d Ever drinkers 46 (56.8) 50 (58.8) 0.79 250 (62.8) 213 (59.2) 0.28 296 (61.9) 263 (59.1) 0.38
Gastric ulcer history Positive (+) 14 (21.9) 9 (14.1) 0.25 62 (17.8) 53 (19.1) 0.69 76 (18.5) 62 (18.1) 0.91
aIncidence gastric cancer cases identified in December 2005 and their age-sex matched controls from the KMCC.
bNewly identified and prevalent gastric cancer cases from the KMCC and newly enrolled gastric cancer cases from Chungnam University Hospital and Hanyang
University GURI Hospital and their age-sex matched controls from the KMCC.
cEver smokers were defined as former and current smokers.
dEver drinkers were defined as former and current drinkers.
doi:10.1371/journal.pone.0021155.t001
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2.06], respectively). Moreover, Dock180 rs4635002 and C3G
rs7853122 showed significantly decreased risk of gastric cancer in
both analyses (OR=0.60, [95% CI: 0.42–0.84], OR=0.61, [95%
CI: 0.43–0.87] for Dock180 rs4635002; OR=0.59, [95% CI:
0.45–0.77], OR=0.59, [95% CI: 0.45–0.76] for C3G rs7853122).
There was no heterogeneity across the studies (Cochran Q test,
p.0.05) except for rs10901081 (p=0.040) (Table 3).
Discussion
In our multi-stage genetic analysis, three SNPs, ERK rs5999749,
Dock180 rs4635002 and C3G rs7853122, showed strong associa-
tions with gastric cancer and may be important regulatory factors in
the CagA signal transduction pathway.
Extracellular signal-regulated kinase (ERK), also known as mito-
gen-activated protein kinase (MAPK), is an important integration
point for multiple cellular signals that regulates various oncogenic
responses. The ERK signal pathway interacts with a considerable
number of substrates, including protein kinases, phosphatases, cyto-
skeletal components, apoptosis regulators, and a range of other
signaling-related molecules [21]. CagA signaling is one of the
streams involved intheERKsignalcascade. Numerous studies have
reported that CagA-positive H. pylori can activate ERK in gastric
epithelial cells to promote inappropriate cellular functions [11,21,
22,23]. Moreover, interaction between CagA and signal transduc-
tionproteinspromotesERKsignalinginconjunctionwith Ras,Mek
andNF-kB,inducinggastriccarcinogenesis.Incellularmechanisms,
ERK appears to be involved in a wide variety of cellular processes.
Thus, the host gene of ERK protein may be more important in
determining protein expression and capacity. The results of this
study demonstrate that ERK rs5999749 is primarily selected in
SNP-based analysis and retains its strong association with gastric
cancer in the final combined analyses. This supports that its genetic
effect can play a critical role in gastric carcinogenesis equal to its
protein activity level at the cellular stage.
Dock180, synonymous with a dedicator of cytokinesis 1, is a
180 kDa protein downstream-combining molecule of Crk and
Table 2. Significant SNPs for candidate genes involved in downstream signaling pathways activated by CagA associated with
gastric cancer in the discovery phase.











e OR (95% CI)
f
ERK rs5999749
g 13 C ( 9.4) 22 20517660 0.0012 0.0011 2.83 (1.42–5.65)
Dock180 rs9418677
g,h 103 C (40.5) 10 128695397 0.0052 0.0048 1.90 (1.18–3.05)
rs4635002
g A (11.3) 128752669 0.0119 0.0168 0.44 (0.18–1.07)
rs7068941 A (11.8) 128718078 0.0418 0.0667 0.41 (0.17–0.99)
rs7917277 T (11.8) 128754664 0.0418 0.0667 0.41 (0.17–0.99)
rs9418832 A (11.8) 128757891 0.0418 0.0667 0.41 (0.17–0.99)
rs9418737 A (11.8) 128757840 0.0418 0.0667 0.41 (0.17–0.99)
C3G rs10901081
g 30 A (21.2) 9 133586496 0.0109 0.0103 0.49 (0.27–0.91)
rs7853122
g G (17.1) 133570432 0.0199 0.0248 0.47 (0.24–0.94)
rs4991743 A (17.1) 133597568 0.0199 0.0248 0.47 (0.24–0.94)
rs7047157 C (17.1) 133503399 0.0199 0.0248 0.47 (0.24–0.94)
rs4474069 T (17.5) 133501207 0.0248 0.0260 0.49 (0.25–0.98)
rs1544305 C (16.5) 133480201 0.0355 0.0361 0.50 (0.25–1.02)
Rap1 rs530801
g 16 A (34.5) 1 111968778 0.0184 0.0186 0.57 (0.35–0.94)
rs558989 G (32.9) 112043318 0.0207 0.0209 0.57 (0.34–0.95)
rs17028287 T ( 4.2) 112046321 0.0215 0.0238 2.46 (0.96–6.28)
rs571020 G (33.9) 112002851 0.0244 0.0266 0.59 (0.37–0.96)
rs846261 A (32.4) 112054920 0.0305 0.0378 0.60 (0.36–0.99)
Src rs747182
g 5 G (12.9) 20 35416303 0.0224 0.0188 1.80 (0.99–3.26)
CrkL rs5761368 2 A ( 9.4) 22 19607471 0.0281 0.0344 2.00 (1.01–3.96)
Mek rs4255740 6 T (35.3) 15 64559061 0.0432 0.0426 0.58 (0.35–0.98)
rs16949924 C (35.3) 64514651 0.0432 0.0426 0.58 (0.35–0.98)
Crk rs8064892 6 C (14.7) 17 1283132 0.0477 0.0602 0.51 (0.24–1.07)
rs8073032 C (14.7) 1283157 0.0477 0.0602 0.51 (0.24–1.07)
aTotal number of selected SNPs within each candidate gene.
bMinor allele frequency among controls.
cChromosome number.
dRaw p-values calculated in the trend model with a cut-off level #0.01.
e100,000 permutations for single SNP in the trend model.
fAdjusted for age, smoking (never vs. ever), H. pylori infection (positive vs. negative) and CagA seropositivity (positive vs. negative).
gSeven representative SNPs with a raw or permutated p value,0.02 identified in the discovery phase were analyzed in the extension phase.
hExcluded due to a SNP call rate ,95%.
*All BH-FDR p-values were not significant (p.0.05).
doi:10.1371/journal.pone.0021155.t002
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cluding cell spreading, cell migration, and actin cytoskeletal orga-
nization through activation of Rac1 [24,25,26,27,28]. This protein
is one of the Crk-downstream proteins involved in the cascade of
CagA and Crk signaling through the Crk-Codk180-ELMo path-
way [9]. Similarly, C3G known as Rap guanine nucleotide
exchange factor (GEF) 1 (RAPGEF1) also interacts with the Crk
[29]. Previous studies demonstrated that the Crk-C3G-Rap1
signaling can activate the ERK cascade and induce apoptosis, cell
growth, migration, adhesion and mortality [30,31,32]. In human
carcinogenesis, the C3G gene appears to play a crucial role by
itself. Alteration of the C3G genetic activity via amplification or
methylation is associated with several cancers such as lung, gas-
trointestinal and gynecological cancers [33,34]. Although it is not
exactly well known whether the genetic variants of the Dock
180 and C3G gene are linked to gastric carcinogenesis, our study
Table 3. Association between representative SNPs and gastric cancer risk in 479 gastric cancer cases and 445 controls.
Discovery phase
a Extension phase
b Total gastric cancer cases vs. controls
GENE SNP MAF
c (%) OR (95% CI)
d MAF
c (%) OR (95% CI)
d MAF
c (%) OR (95% CI)
d,e OR (95% CI)
d,f*
ERK rs5999749 C ( 9.8) 2.83 (1.42–5.65) C (11.0) 1.40 (1.04–1.89) C (10.5) 1.57 (1.20–2.07) 1.56 (1.19–2.06)
Dock180 rs4635002 A (11.3) 0.44 (0.18–1.07) A (11.1) 0.65 (0.44–0.94) A (11.1) 0.60 (0.42–0.84) 0.61 (0.43–0.87)
C3G rs7853122 G (17.1) 0.47 (0.24–0.94) G (18.2) 0.61 (0.46–0.81) G (18.0) 0.59 (0.45–0.77) 0.59 (0.45–0.76)
rs10901081 A (21.2) 0.49 (0.27–0.91) A (18.2) 0.98 (0.75–1.27) A (18.5) 0.87 (0.68–1.10) 0.88 (0.69–1.12)
Rap1 rs530801 A (34.5) 0.57 (0.35–0.94) A (25.8) 0.93 (0.73–1.19) A (27.5) 0.85 (0.68–1.05) 0.85 (0.68–1.05)
Src rs747182 G (12.9) 1.80 (0.99–3.26) G (16.7) 1.05 (0.80–1.39) G (16.0) 1.17 (0.92–1.50) 1.16 (0.90–1.48)
aIncidence gastric cancer case identified in December 2005 and their age-sex matched controls from the KMCC.
bNewly identified and prevalent gastric cancer cases from the KMCC and newly enrolled gastric cancer cases from Chungnam University Hospital and Hanyang
University GURI Hospital and their age-sex matched controls from the KMCC.
cMinor allele frequency among controls.
dAdjusted for age, smoking (never vs. ever), H. pylori infection (positive vs. negative)and CagA seropositivity (positive vs. negative).
ePooled analysis including all gastric cases and controls form each study dataset.
fMeta analysis using fixed effect model for combined analysis.
*No heterogeneity across the phases (Cochran Q test, P-heterogeneity .0.05) except for rs10901081 (p=0.040).
doi:10.1371/journal.pone.0021155.t003
Figure 1. CagA oncogenic effect via the ERK signal pathway. The CagA interaction can stimulate the downstream signals in the ERK cascade
linked to aberrant cellular functions that leads to gastric carcinogenesis. In this process, the genetic effects of ERK, Dock180 and C3G play critical roles
equal to their protein activity levels at the cellular stage.
doi:10.1371/journal.pone.0021155.g001
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rs7853122, are significantly associated with risk of gastric cancer,
and thus may be a susceptible gene in the development of gastric
cancer.
Based on the present results and review of cellular mechanisms
[3,9,11,21,22,23,24,30], CagA oncogenicity induced by activation
of the ERK signal pathway can be infered (Figure 1). The CagA
interaction with binding molecules such as Src, Crk, GRB2 and
SHP-2 stimulates the downstream signals in the ERK cascade
linked to aberrant cellular functions that leads to gastric carcino-
genesis. During this process, the genetic effects of ERK, Dock180
and C3G can play critical roles equal to their protein activities.
These results provide support for the genetic and cellular impor-
tance of those molecules.
Our genetic analysis presented plausible evidence on genetic
variants of the ERK signal transduction pathway activated by
CagA, but several limitations should be noted. First, the number of
study subjects was insufficient to ensure statistical power to assess
the exact association between selected SNPs and gastric cancer
risk. Second, due to the small sample size and lack of cardiac
gastric cancer patients (less than 5%), we could not conduct
stratified analysis according to gastric cancer type, cardiac vs. non-
cardiac. Therefore, results should be interpreted with caution.
This study indicates that genes involved in the ERK signal
transduction pathway activated by CagA can modify risk of gastric
cancer. ERK, Dock180 and C3G genes may play important roles
in the development of gastric cancer. Replication studies in other
populations will allow us to elucidate gastric cancer pathological
mechanisms. Further biological studies focused on these genes can
clarify their roles in gastric carcinogenesis.
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